CardioRenal
- Company typePrivate
- Founded2012
- HeadquartersStrasbourg, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
CardioRenal firmographics
Firmographics- Name
- CardioRenal
- Legal name
- CardioRenal
- Website
- https://cardio-renal.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
CardioRenal industry classification
Industry- Product category
- Connected Medical Devices
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Services-Health Services (8000)
- akta.pro primary industry
- Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status) (HLAHAKAJ)
- akta.pro secondary industries
- Nephrology Telemedicine Platforms (HLALAGAI), Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), Chronic Care & Remote Patient Monitoring (RPM) Platforms (HLALABAF)
Keywords
Where CardioRenal is headquartered
LocationHeadquarters
- HQ city
- Strasbourg
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
CardioRenal business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Connected Medical Device Sales: Sale of connected medical devices for remote monitoring of blood biomarkers in CKD patients
Go-to-market motion1 record
CardioRenal product offering
Product offeringCore offering
CardioRenal develops a connected medical device and integrated remote monitoring platform that enables home-based monitoring of blood biomarkers for chronic kidney disease (CKD) patients. The platform is designed to optimize patient care, support treatment management, and reduce the need for clinic visits by collecting clinical data outside healthcare facilities.
Product overview
CardioRenal offers a remote monitoring solution for chronic kidney disease (CKD) patients, consisting of an integrated platform and a connected medical device. The integrated platform enables remote monitoring of blood biomarkers to optimize patient care, while the connected medical device (planned for launch in 2023) is designed for home-based use by CKD patients. The company is pursuing CE marking regulatory approval for its medical device platform.
Differentiator
Problem solved
Functional benefit
Products and services
- Integrated Remote Monitoring Platform An integrated platform enabling remote monitoring of blood biomarkers for chronic kidney disease (CKD) patients, designed to optimize patient care and support treatment management at home.
- Connected Medical Device A connected medical device for home-based remote monitoring of CKD patients, enabling blood biomarker tracking and clinical data collection outside healthcare facilities.
Companies that use CardioRenal
Customer profileSegments1 record
Ideal customer profiles1 record
CardioRenal technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
CardioRenal partnerships and signals
Strategic signalScale indicators3 records
Recent moves5 records
Expansion highlights5 records
CardioRenal competitors and assessment
Company assessmentDirect peers
- Renalytix: Renalytix develops AI-enabled diagnostic and prognostic solutions for chronic kidney disease, including KidneyIntelX for early-stage CKD risk assessment. It is a direct peer to CardioRenal because both target biomarker-driven CKD decision support, with CardioRenal focused on home blood-biomarker remote monitoring and Renalytix on blood/urine-based risk stratification.
- Healthy.io: Healthy.io is a home-based diagnostics company best known for smartphone-based urinalysis (including ACR testing for kidney disease) and other home test kits. It is a direct peer to CardioRenal because both deliver home-based kidney-related diagnostic testing to enable remote CKD monitoring and management.
- HemoCue (Radiometer): HemoCue, part of Radiometer/Danaher, manufactures point-of-care blood diagnostic devices used in clinics, homes, and resource-limited settings. It is a direct peer to CardioRenal because both provide connected point-of-care blood biomarker measurement devices applicable to CKD patient monitoring.
- Vivify Health: Vivify Health provides a remote patient monitoring platform that connects patients at home with care teams using connected devices and mobile apps. It is a direct peer to CardioRenal because both operate integrated device-plus-platform remote patient monitoring solutions targeting chronic care populations.
Emerging players
- BioIntellisense: BioIntellisense offers continuous multi-parameter remote patient monitoring using a single wearable adhesive sensor capturing vital signs and biomarkers. It is an emerging player peer to CardioRenal because both pursue connected, continuous biomarker monitoring in the home, though BioIntellisense focuses on multi-parameter wearables while CardioRenal focuses on blood biomarkers for CKD.
Broad incumbents
- Fresenius Medical Care: Fresenius Medical Care is the global leader in dialysis products and kidney-care services, operating a vast network of dialysis clinics and offering connected monitoring solutions for ESRD patients. It is a broad incumbent peer to CardioRenal because both serve the CKD/ESRD patient population with monitoring technologies, though Fresenius is far larger and clinic-anchored.
- DaVita: DaVita is a leading US-based kidney-care services provider operating thousands of dialysis centers and increasingly investing in home dialysis and remote monitoring for CKD patients. It is a broad incumbent peer because both companies operate in the CKD care continuum and pursue remote monitoring for chronic kidney patients, though DaVita is a clinical services incumbent rather than a hardware startup.
- Outset Medical: Outset Medical developed the Tablo Hemodialysis System for home and clinic use, expanding home-based kidney-care options. It is a broad incumbent peer to CardioRenal because both target home-based kidney care with connected devices, though Outset Medical's device is for dialysis while CardioRenal's is for remote blood biomarker monitoring.
- Abbott: Abbott is a global diagnostics and medical device leader with extensive blood-biomarker testing platforms (e.g., i-STAT) and a chronic-care remote monitoring portfolio. It is a broad incumbent peer to CardioRenal because both operate in blood-biomarker measurement and chronic-care monitoring, though Abbott's reach is far broader across multiple clinical areas.
- Medtronic: Medtronic is a global medical device company with cardiac and renal diagnostics, remote monitoring (e.g., LINQ insertable cardiac monitor), and broader chronic-care portfolios. It is a broad incumbent peer to CardioRenal because both address cardio-renal chronic disease monitoring with connected medical devices, though Medtronic's portfolio is far broader and its scale dwarfs CardioRenal.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
CardioRenal social profiles
Digital presenceCardioRenal compliance and trust
Trust signalCompliance1 record
CardioRenal financial estimates
Financial estimateRevenue estimate
Valuation estimate
CardioRenal leadership team
Management profileNumber of profiles
CardioRenal funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CardioRenal M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CardioRenal
What does CardioRenal do?
CardioRenal develops a connected medical device and integrated remote monitoring platform that enables home-based monitoring of blood biomarkers for chronic kidney disease (CKD) patients. The platform is designed to optimize patient care, support treatment management, and reduce the need for clinic visits by collecting clinical data outside healthcare facilities.
Is CardioRenal a public or private company?
CardioRenal is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was CardioRenal founded?
CardioRenal was founded in 2012. It employs 11 to 50 people.
Where is CardioRenal based?
CardioRenal is headquartered in Strasbourg, France, in the Europe region.
How does CardioRenal make money?
One revenue line is on record: connected Medical Device Sales.
Who are CardioRenal's main competitors?
Direct peers on record are Renalytix, Healthy.io, HemoCue (Radiometer) and Vivify Health. BioIntellisense is listed as an emerging player. Broad incumbents are Fresenius Medical Care, DaVita, Outset Medical, Abbott and Medtronic.
Does CardioRenal have an API?
No public API is recorded for CardioRenal.
What industry is CardioRenal in?
CardioRenal's product category is Connected Medical Devices. Its primary akta.pro industry code is HLAHAKAJ, Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status), with a secondary code of HLALAGAI, Nephrology Telemedicine Platforms. Its SIC code is 3845.